RNA polymerase II subunit MGenealiases: GRINL1A · Gdown · Gdown1
Q-omics provides the consensus-scored POLR2M profile across patient tissues and cancer cell-line models. POLR2M expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, POLR2M is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, POLR2M RNA expression shows 19,833 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and HNSC as cancer lineages where POLR2M shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for POLR2M — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes POLR2M survival associations across molecular data types. POLR2M RNA expression shows survival associations in the most cancer types (28), followed by mutation status (2) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible POLR2M RNA expression–survival associations across cancer types. High POLR2M expression shows unfavorable associations in UVM, OV, ESCA and SCLC, but favorable associations in KIRC and THYM. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for POLR2M RNA expression.
This table summarizes POLR2M tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for POLR2M. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. POLR2M shows lower tumor expression in UCEC, LUAD and BRCA and higher tumor expression in HNSC, LIHC and CHOL. The HNSC box plot shows higher POLR2M RNA expression in tumor versus normal tissue (log2 FC = +0.619, t-test p < 0.001).
This table shows molecular features associated with POLR2M in patient tissues and cancer cell lines. In patient samples, POLR2M shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, POLR2M RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and LARGE_INTESTINE.
